Cirius Therapeutics Reaches Enrollment Target in Phase 2b EMMINENCE Trial in NASH
Cirius Therapeutics announced that it has reached its enrollment target in its Phase 2b EMMINENCE trial for its lead program MSDC-0602K in more than 380 patients with NASH and liver…
Read More...
Read More...
